查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2047912

膈肌起搏治療系統市場－全球產業規模、佔有率、趨勢、機會、預測：按產品、應用、地區和競爭對手分類，2021-2031年

Diaphragm Pacing Therapy System Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Application, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球膈肌起搏治療系統市場預計將從 2025 年的 79.2 億美元成長到 2031 年的 101.1 億美元，複合年成長率為 4.15%。

這種植入式醫療設備透過電刺激橫膈神經促進橫膈膜收縮，模擬自然呼吸，進而幫助慢性呼吸衰竭患者。該市場的成長主要受全球高位脊髓損傷和肌萎縮側索硬化症（ALS）盛行率不斷上升的驅動。這些疾病使得人們對傳統機械通氣以外的長期呼吸支持解決方案的需求顯著增加。此外，臨床上需要減輕人工呼吸器相關性肺炎的發生率，並透過提高患者的活動能力來改善其生活品質（QOL），這極大地加速了全球範圍內此類起搏系統的應用。然而，市場擴張的主要障礙是設備本身及其植入手術的高成本，尤其是在醫療機構對成本敏感且保險覆蓋範圍有限的情況下。儘管患者數量不斷增加，但不一致的報銷政策進一步阻礙了患者獲得這項關鍵技術。例如，根據世界衛生組織（WHO）預測，到2024年，全球將有超過1500萬人患有脊髓損傷，這構成了一個需要永續呼吸系統護理的重要群體。

市場概覽
預測期 2027-2031
市場規模：2025年 79.2億美元
市場規模：2031年 101.1億美元
複合年成長率：2026-2031年 4.15%
成長最快的細分市場 脊髓損傷
最大的市場 北美洲

市場促進因素

脊髓損傷和肌萎縮側索硬化症 (ALS) 發病率的不斷上升是全球膈肌起搏系統市場的主要驅動力，也因此產生了對先進呼吸支持的迫切臨床需求。高位脊髓損傷通常會導致橫膈膜麻痺，需要永久性機械呼吸系統護理，這會嚴重影響患者的活動能力和整體生活品質。隨著醫療專業人員越來越重視恢復患者的自然呼吸功能，膈肌起搏系統在這一不斷成長的患者群體中的應用也日益普及。例如，根據美國國家脊髓損傷統計中心的數據，美國每年每百萬人中約有 54 例脊髓損傷病例，相當於每年約有 18,421 例新的創傷性脊髓損傷病例，這凸顯了對長期呼吸系統護理解決方案的持續需求。同時，長期脫離人工呼吸器的臨床趨勢也顯著地推動了市場擴張。這主要是由於需要降低高昂的運作成本並減少人工呼吸器相關性肺炎等併發症。本院正日益重視橫膈膜起搏，以促進患者早期脫離侵入性人工呼吸器。這減輕了加護病房長期住院對醫療系統的經濟負擔。這種轉變的經濟合理性顯而易見：根據《重症監護醫學雜誌》2024年4月刊報道，每次人工呼吸器相關事件的直接額外成本估計為3227.84歐元，這促使人們採用起搏系統來最大限度地降低感染風險。此外，需要此類干預的神經退化性疾病的高發生率也為該市場帶來了機會。美國疾病管制與預防中心（CDC）估計，到2025年，美國將有約33,000例肌萎縮側索硬化症（ALS）病例，這代表著一個龐大的醫療設備使用群體。

市場挑戰

膈肌起搏系統及其手術植入的高昂成本是限制全球市場成長的主要因素。高昂的購買和手術費用是推廣應用的一大障礙，尤其是在醫療預算緊張的地區。這種經濟壓力常常迫使醫療機構選擇初始投資成本較低的傳統機械通氣，儘管起搏系統具有長期的臨床效益。因此，高昂的價格直接阻礙了設備的普及，並限制了願意投資這項專業技術的醫療機構數量。此外，缺乏統一的保險報銷機制加劇了這一挑戰，將經濟責任轉嫁到本已面臨沉重經濟負擔的患者身上。當保險公司拒絕或限制這些設備的報銷時，由此產生的自付費用對於大多數符合條件的患者來說將難以承受。例如，美國肌萎縮側索硬化症協會估計，到2025年，每位肌萎縮側索硬化症患者的年度照護費用將達到約25萬美元，這意味著心律調節器技術的額外成本對許多家庭來說可能難以負擔。這將縮小目標市場，阻礙整個產業的整體收入成長。

市場趨勢

經靜脈節律解決方案的出現，為人工呼吸器撤機患者帶來了突破性的技術進步，使治療重點從傳統的外科植入轉向了創傷較小的導管介入方法。這一趨勢包括開發用於中心靜脈置入的臨時性神經刺激系統，從而避免了腹腔鏡手術，並降低了重症患者提供永久性起搏。臨床進展也十分顯著，Lungpacer Medical公司於2025年2月公佈了STIMULUS試驗的正面結果。該試驗成功招募了19名患者，旨在研究經靜脈膈神經刺激在改善機械通氣期間血流動力學的療效。同時，適應症的擴大，包括人工呼吸器相關性膈肌功能障礙（VIDD），顯著拓寬了目標患者群體，使其不再局限於慢性脊髓損傷患者，而是涵蓋了急性重症監護患者。醫療專業人員日益認知到正壓通氣導致的橫膈膜萎縮進展迅速，因此擴大採用起搏療法來緩解呼吸器相關性膈肌功能障礙（VIDD），並促進患者儘早脫離人工呼吸器。這項擴展的臨床適應症旨在解決大量因膈肌無力而難以脫離人工呼吸器的患者的問題，從而使該設備從針對小眾罕見病的專用產品轉變為重症監護的重要工具。為了凸顯這項新臨床重點的重要性，Lungpacer Medical 於 2025 年 3 月宣布，其 STARI II 期可行性研究已獲得臨床實驗醫療設備豁免（IDE）。該試驗每年將在美國招募約 250 萬名人工呼吸器依賴患者，旨在降低人工呼吸器相關併發症的發生率。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球橫膈膜起搏治療系統市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 產品類別（體外膈肌節律器、橫膈膜心律調節器）
    • 依應用領域（脊髓損傷、肌萎縮側索硬化症等）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美橫膈膜起搏治療系統市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲橫膈膜起搏治療系統市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區橫膈膜起搏治療系統市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東與非洲膈肌節律治療系統市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美橫膈膜起搏治療系統市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球橫膈膜起搏治療系統市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • LUNGPACER MEDICAL INC.
  • Avery Biomedical Devices, Inc.
  • Synapse Biomedical Inc
  • Astrotech Corp.
  • AstraZeneca PLC
  • Novartis AG
  • Boehringer Ingelheim
  • Respironics Ltd
  • Johnson & Johnson
  • PneumRx, LLC

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 20597

The Global Diaphragm Pacing Therapy System Market is projected to expand from USD 7.92 Billion in 2025 to USD 10.11 Billion by 2031, reflecting a 4.15% compound annual growth rate. This implantable medical device aids patients with chronic respiratory insufficiency by electrically stimulating the phrenic nerve to induce diaphragm contractions, thereby mimicking natural breathing. The market's growth is fundamentally propelled by the increasing global prevalence of high-level spinal cord injuries and Amyotrophic Lateral Sclerosis, which create a critical demand for long-term respiratory support solutions beyond traditional mechanical ventilation.Furthermore, the clinical imperative to mitigate ventilator-associated pneumonia and enhance patient quality of life through improved mobility significantly accelerates the worldwide adoption of these pacing systems. However, substantial barriers to market expansion include the high cost of the device and its surgical implantation, particularly in healthcare settings where cost sensitivity and limited insurance coverage are prevalent. Inconsistent reimbursement policies further impede patient access to this vital technology, despite the escalating patient population; for instance, the World Health Organization reported over 15 million individuals globally were living with a spinal cord injury in 2024, representing a key demographic in need of sustainable respiratory management.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 7.92 Billion
Market Size 2031USD 10.11 Billion
CAGR 2026-20314.15%
Fastest Growing SegmentSpinal Cord Injury
Largest MarketNorth America

Market Driver

The increasing incidence of spinal cord injuries and Amyotrophic Lateral Sclerosis stands as a primary catalyst for the Global Diaphragm Pacing Therapy System Market, creating a pressing clinical need for advanced respiratory assistance. High-level spinal cord trauma often results in diaphragm paralysis, necessitating permanent ventilatory support that significantly compromises patient mobility and overall quality of life. As healthcare providers increasingly seek to restore natural breathing mechanics, the adoption of diaphragm pacing systems is accelerating within this growing patient demographic. For example, the National Spinal Cord Injury Statistical Center reported an annual incidence of approximately 54 cases per one million people in the United States, equating to about 18,421 new traumatic spinal cord injury cases each year, underscoring the consistent demand for long-term respiratory management solutions.Concurrently, a clinical shift away from prolonged mechanical ventilation is significantly boosting market expansion, driven by the necessity to reduce high operational costs and mitigate complications such as ventilator-associated pneumonia. Hospitals are increasingly prioritizing diaphragm pacing to facilitate earlier weaning from invasive ventilators, thereby alleviating the financial burden on healthcare systems associated with extended intensive care stays. The economic rationale for this transition is evident, with direct additional costs per ventilator-associated event episode calculated at €3,227.84, according to the Journal of Critical Care Medicine in April 2024, thus incentivizing the adoption of pacing systems to minimize infection risks. Furthermore, the market benefits from the substantial prevalence of neurodegenerative conditions requiring such interventions; the Centers for Disease Control and Prevention estimated nearly 33,000 cases of Amyotrophic Lateral Sclerosis in the United States in 2025, representing a significant demographic for device utilization.

Market Challenge

The substantial financial outlay associated with the Diaphragm Pacing Therapy System and its surgical implantation procedure represents a primary impediment to the global market's growth. Elevated acquisition and operative expenses create significant barriers to adoption, particularly in healthcare regions operating under stringent budgetary constraints. This economic pressure often compels healthcare providers to opt for traditional mechanical ventilation, which entails lower upfront capital expenditure, despite the long-term clinical advantages offered by pacing systems. Consequently, the high price point directly hinders the rate of device uptake and restricts the number of medical facilities willing to invest in this specialized technology.Furthermore, the absence of consistent reimbursement coverage exacerbates this challenge by transferring the financial responsibility onto patients, who are often already contending with severe economic strain. When insurance policies either deny or impose limitations on coverage for these devices, the resulting out-of-pocket expenses become prohibitive for the majority of the eligible patient population. For instance, the ALS Association reported an estimated annual cost of approximately $250,000 for caring for a person with the disease in 2025, indicating that the additional cost of pacing technology can become financially unmanageable for many families, thereby narrowing the accessible market and impeding the industry's overall revenue expansion.

Market Trends

The emergence of transvenous pacing solutions for ventilator weaning signifies a pivotal technological evolution within the market, shifting focus from traditional surgical implantation toward less invasive, catheter-based methodologies. This trend involves the development of temporary neurostimulation systems designed for central vein insertion, thereby obviating the need for laparoscopic surgery and reducing risks of infection and surgical trauma in critically ill individuals. These systems are specifically engineered to offer temporary diaphragmatic support to strengthen the muscle during the weaning process, rather than providing permanent pacing for chronic paralysis. Clinical advancements are evident, with Lungpacer Medical reporting positive results from its STIMULUS Trial in February 2025, which successfully enrolled 19 patients to investigate transvenous diaphragm neurostimulation for improving hemodynamic performance during mechanical ventilation.Concurrently, the expansion of clinical indications to encompass Ventilator-Induced Diaphragm Dysfunction (VIDD) is considerably widening the addressable patient demographic beyond chronic spinal cord injury cases to include acute intensive care settings. Healthcare providers are increasingly recognizing the rapid onset of diaphragm atrophy caused by positive-pressure ventilation, prompting the application of pacing therapies to mitigate VIDD and accelerate patient liberation from mechanical support. This clinical expansion aims to address the significant number of patients who struggle to wean due to diaphragm weakness, thereby transforming the device from a specialized orphan product into an essential critical care tool. Highlighting the scale of this new clinical emphasis, Lungpacer Medical announced an Investigational Device Exemption (IDE) for its STARI Phase 2 Feasibility Clinical Trial in March 2025, targeting nearly 2.5 million mechanically ventilated United States patients annually to reduce the incidence of ventilator-associated injury.

Key Market Players

  • LUNGPACER MEDICAL INC.
  • Avery Biomedical Devices, Inc.
  • Synapse Biomedical Inc
  • Astrotech Corp.
  • AstraZeneca PLC
  • Novartis AG
  • Boehringer Ingelheim
  • Respironics Ltd
  • Johnson & Johnson
  • PneumRx, LLC

Report Scope

In this report, the Global Diaphragm Pacing Therapy System Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Diaphragm Pacing Therapy System Market, By Product

  • External Diaphragm Pacemaker
  • Diaphragm Pacemaker

Diaphragm Pacing Therapy System Market, By Application

  • Spinal Cord Injury
  • Amyotrophic Lateral Sclerosis
  • Others

Diaphragm Pacing Therapy System Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Diaphragm Pacing Therapy System Market.

Available Customizations:

Global Diaphragm Pacing Therapy System Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Diaphragm Pacing Therapy System Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (External Diaphragm Pacemaker, Diaphragm Pacemaker)
    • 5.2.2. By Application (Spinal Cord Injury, Amyotrophic Lateral Sclerosis, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Diaphragm Pacing Therapy System Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Diaphragm Pacing Therapy System Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Application
    • 6.3.2. Canada Diaphragm Pacing Therapy System Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Application
    • 6.3.3. Mexico Diaphragm Pacing Therapy System Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Application

7. Europe Diaphragm Pacing Therapy System Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Diaphragm Pacing Therapy System Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Application
    • 7.3.2. France Diaphragm Pacing Therapy System Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Diaphragm Pacing Therapy System Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Diaphragm Pacing Therapy System Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Diaphragm Pacing Therapy System Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Application

8. Asia Pacific Diaphragm Pacing Therapy System Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Diaphragm Pacing Therapy System Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Application
    • 8.3.2. India Diaphragm Pacing Therapy System Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Application
    • 8.3.3. Japan Diaphragm Pacing Therapy System Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Application
    • 8.3.4. South Korea Diaphragm Pacing Therapy System Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Diaphragm Pacing Therapy System Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Application

9. Middle East & Africa Diaphragm Pacing Therapy System Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Diaphragm Pacing Therapy System Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Application
    • 9.3.2. UAE Diaphragm Pacing Therapy System Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Application
    • 9.3.3. South Africa Diaphragm Pacing Therapy System Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Application

10. South America Diaphragm Pacing Therapy System Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Diaphragm Pacing Therapy System Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Application
    • 10.3.2. Colombia Diaphragm Pacing Therapy System Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Application
    • 10.3.3. Argentina Diaphragm Pacing Therapy System Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Diaphragm Pacing Therapy System Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. LUNGPACER MEDICAL INC.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Avery Biomedical Devices, Inc.
  • 15.3. Synapse Biomedical Inc
  • 15.4. Astrotech Corp.
  • 15.5. AstraZeneca PLC
  • 15.6. Novartis AG
  • 15.7. Boehringer Ingelheim
  • 15.8. Respironics Ltd
  • 15.9. Johnson & Johnson
  • 15.10. PneumRx, LLC

16. Strategic Recommendations

17. About Us & Disclaimer